Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 7
- Registration Number
- NCT05209152
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT05201066
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Uni of Massachusetts Medical Center, Worcester, Massachusetts, United States
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- LLS PedAL Initiative, LLC
- Target Recruit Count
- 98
- Registration Number
- NCT05183035
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Alliance for Childhood Diseases dba Cure 4 The Kids Foundation, Las Vegas, Nevada, United States
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2023-01-31
- Target Recruit Count
- 40
- Registration Number
- NCT05182957
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05179213
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
- Conditions
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2022-01-03
- Target Recruit Count
- 180
- Registration Number
- NCT05175508
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 218
- Registration Number
- NCT05168202
- Locations
- 🇺🇸
Local Institution - 0001, Houston, Texas, United States
🇦🇺Local Institution - 0027, Wollongong, New South Wales, Australia
🇦🇺Local Institution - 0006, Clayton, Victoria, Australia
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05155709
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
🇺🇸Oregon Health Sciences University ., Portland, Oregon, United States
🇺🇸Texas Oncology Sammons Cancer Center Sammons Cancer Center (SC), Dallas, Texas, United States
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 44
- Registration Number
- NCT05144243
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 232253, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University /ID# 233704, Wenzhou, Zhejiang, China
🇨🇳Duplicate_The Affiliated Hospital of Guizhou Medical University /ID# 232465, Guiyang, China
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05140811
- Locations
- 🇨🇳
The first affiliated hospital of nanchang University, Nanchang, China
🇨🇳Shanghai sixth's hospital, Shanghai, China
🇨🇳Ganzhou People's Hospital, Ganzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.